Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

Abstract Background Small cell lung cancer (SCLC) is a highly aggressive disease with a poor prognosis. Although most patients initially respond to topoisomerase inhibitors, resistance rapidly emerges. The aim, therefore, is to overcome resistance to topoisomerase I (irinotecan) or II (etoposide) in...

Full description

Bibliographic Details
Main Authors: Miwako Omori, Rintaro Noro, Masahiro Seike, Kuniko Matsuda, Mariko Hirao, Aya Fukuizumi, Natsuki Takano, Akihiko Miyanaga, Akihiko Gemma
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Thoracic Cancer
Subjects:
ATP‐binding cassette transporters
drug resistance
small cell lung cancer
topoisomerase I inhibitor
topoisomerase II inhibitor
Online Access:https://doi.org/10.1111/1759-7714.14527

Internet

https://doi.org/10.1111/1759-7714.14527

Similar Items